Chargement en cours...
Trial Watch: Toll-like receptor agonists in cancer immunotherapy
Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved by US regulatory agencies for use in cancer patients. Additionally, the potential of hitherto experimental TLR ligands to mediate...
Enregistré dans:
| Publié dans: | Oncoimmunology |
|---|---|
| Auteurs principaux: | , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Taylor & Francis
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6279325/ https://ncbi.nlm.nih.gov/pubmed/30524908 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1526250 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|